Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Bladder cancer (BC) and renal cell carcinoma (RCC) are common urinary tract malignancies.
• While molecular-targeted therapies have advanced RCC treatment, BC lacks approved targeted therapeutics.
• MicroRNAs (miRNAs), small noncoding RNAs regulating gene expression, are implicated in cancer pathogenesis.

Purpose of the Study:

• To review recent miRNA expression signatures in BC and RCC.
• To identify consistently dysregulated miRNAs across multiple studies for both cancers.
• To explore the contrasting expression patterns of the miR-200 family in BC and RCC.

Main Methods:

• Systematic review of published miRNA expression signatures for BC and RCC.
• Focus on miRNAs showing consistent downregulation or upregulation across studies.
• In silico analysis to predict target genes of key miRNAs, particularly the miR-200 family.

Main Results:

• Identification of specific miRNA expression signatures associated with BC and RCC.
• Discovery of opposite expression trends for the miR-200 family miRNAs (miR-141/200c, miR-200a/200b/429) between BC and RCC.
• In silico analysis provides insights into potential target genes regulated by the miR-200 family in these cancers.

Conclusions:

• Aberrantly expressed miRNAs are crucial in the pathogenesis of BC and RCC.
• The opposing expression of miR-200 family miRNAs in BC versus RCC suggests distinct roles and potential therapeutic avenues.
• Further investigation into miR-200 family targets and mechanisms is warranted for understanding and treating these cancers.